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Abstract: A base mediated 6-endo-trig cyclization of readily accessible enone derived α-amino acids 
has been developed for the direct synthesis of novel 2,6-cis-6-substituted-4-oxo-L-pipecolic acids. A 
range of aliphatic and aryl side-chains were tolerated by this mild procedure to give the target 
compounds in good overall yields. Molecular modeling of the 6-endo-trig cyclization allowed some 
insight as to how these compounds were formed, with the enolate intermediate generated via an 
equilibrium process, followed by irreversible tautomerization/neutralization providing the driving force 
for product formation. Stereoselective reduction and deprotection of the resulting 2,6-cis-6-substituted-
4-oxo-L-pipecolic acids to the corresponding 4-hydroxy-L-pipecolic acids was also performed. 
 
Keywords: α-amino acids, phosphonate ester, aza-Michael reaction, pipecolic acid. 
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INTRODUCTION 
The cyclic nonproteinogenic α-amino acid L-pipecolic acid 1 is metabolized from L-lysine via several 
putative pathways.1 As well as being found in plants and fungi, it has a functional role in the 
mammalian central nervous system in a manner similar to γ-aminobutyric acid (GABA).2,3 L-Pipecolic 
acid 1 is also a component of several pharmacologically active compounds including the antitumour 
antibiotic sandramycin4 and the immunosuppressive agents rapamycin5 and FK506.6 Analogues 
incorporating an oxygen atom, particularly at the 4-position, such as 4-oxo-L-pipecolic acid 2 or 
(2S,4R)-4-hydroxypipecolic acid 3 are also biologically and medicinally important. For example, 4-oxo-
L-pipecolic acid 2 is a key structural element of the cyclic hexadepsipeptide antibiotic virginamycin S1 
4,7 while (2S,4R)-4-hydroxypipecolic acid 3, isolated from the leaves of Calliandra pittieri and 
Strophantus scandeus,8 is a constituent of the synthetic HIV protease inhibitor palinavir 5.9 
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Figure 1. L-Pipecolic acid 1 and oxygenated analogues. 
 
As these compounds are of significant pharmacological and medicinal importance, methods for their 
asymmetric synthesis has received considerable attention.10 For example, Occhiato and co-workers 
 4 
demonstrated the synthesis of (2S,4R)-4-hydroxypipecolic acid 3 using a palladium-catalyzed 
methoxycarbonylation of a 4-alkoxy-substituted δ-valerolactam-derived vinyl triflate as the key step,11 
while the research group of Haufe showed that a (2S,6R)-6-tert-butyl-4-oxopipecolic amide could be 
formed via an acid mediated cascade from a 2-fluorovinyl imidazolidinone.12 Our own research efforts 
have focused on developing stereoselective approaches for the less well-known 6-substituted 4-oxo- and 
4-hydroxypipecolic acids13–15 and recently we reported a one-pot, reductive amination/6-endo-trig 
cyclization of α-amino acids bearing an enone side-chain for the preparation of 2,6-trans-6-substituted-
4-oxo-L-pipecolic acids (Scheme 1a).16 The stereochemical outcome of the 6-endo-trig cyclization was 
rationalized by a Zimmerman-Traxler, chair-like transition state17 which placed both the R-group and 
the N-substituent in a pseudo-equatorial position. To switch the stereochemical outcome of this 6-endo-
trig cyclization and gain access to 2,6-cis-6-substituted-4-oxo-L-pipecolic acids, a more direct, 
intramolecular aza-Michael reaction was proposed (Scheme 1b). Without a substituent on the amine, it 
was believed an alternative chair-like reacting conformer in which the R-group and methyl ester 
moieties both occupy a pseudo-equatorial position would now control the cyclization. Herein, we now 
report the development of a one-pot, deprotection/base mediated 6-endo-trig cyclisation to give 2,6-cis-
6-substituted-4-oxo-L-pipecolic acids. The facile stereoselective reduction of these compounds to the 
corresponding (4R)-hydroxypipecolic acid analogues is also described.  
 
Scheme 1. 6-endo-trig cyclization of enone derived α-amino acids. 
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RESULTS AND DISCUSSION 
To study the scope of the 6-endo-trig cyclization, a range of aryl and alkyl substituted α-amino acid 
derived enones were prepared in four steps from L-aspartic acid 6 (Scheme 2).16,18 Initially, 6 was 
converted under standard conditions and in quantitative yield to N-trityl L-aspartate dimethyl ester 7. 
Regioselective reaction of the β-methyl ester of 7 with 2.2 equivalents of the lithium anion of dimethyl 
methylphosphonate gave exclusively β-ketophosphonate ester 8 in 84% yield.19 Horner-Wadsworth-
Emmons reaction of 8 under mild conditions with a range of aldehydes gave solely the E-enones 9–19 
in 58–96% yield. 
 
Scheme 2. Synthesis of enone derived α-amino acids. 
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The phenyl derived E-enone 9 was selected as the model substrate for discovery and optimization of 
the key cyclization step (Table 1). Initially, conversion to the corresponding 4-oxo-L-pipecolic acids 20 
and 21 was performed as a two-pot process. The trityl protecting group was removed under acidic 
conditions and on basic work-up the amine was isolated in quantitative yield. Attempted intramolecular 
aza-Michael reaction with strong bases such as n-butyl lithium (entry 1) or lithium 
hexamethyldisilazane (entry 2) gave highly complex mixtures of polar compounds with no cyclized 
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products detected. Using sodium carbonate in dichloromethane and milder reaction conditions returned 
only the starting amine (entry 3). A one-pot procedure was next attempted with sodium carbonate added 
to the reaction mixture after the deprotection step was deemed complete (entry 4). This gave cyclised 
products 20 and 21 in 41% yield over the two steps and in a diastereoselective ratio of 75:25, 
respectively.20 Enhanced solvation of the base using the more polar solvent, methanol (c.f. entry 3) 
seemed crucial for successful cyclization of enone 9. Following this observation, the one-pot, two-step 
procedure was investigated using neutral organic bases. Optimal results were achieved using Hünig’s 
base (entry 5) which gave 20 and 21, very cleanly in 85% yield and with the same diastereomeric ratio 
as noted above. The main product, cis-diastereomer 20 was easily isolated in 56% yield using flash 
column chromatography. 
 
Table 1. Optimization of the 6-endo-trig cyclization. 
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9
N
H
CO2Me
O
Ph
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+
N
H
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21  
entry base solvent Temp (ºC) T (h) yield (%) 
1 nBuLi THF –78 24 0 
2 LiHMDS THF 65 24 0 
3 Na2CO3 CH2Cl2 rt 48 0 
4a Na2CO3 MeOH rt 18 41 
5a EtN(iPr)2 MeOH rt 18 85 
a Reactions were performed as one-pot, two-step procedures. 
 
The scope and stereoselectivity of the one-pot, deprotection/6-endo-trig cyclization was then 
investigated using E-enones 10–19 (Table 2). On work-up of all of these reactions, the diastereomeric 
ratio of the cis- and trans-products was recorded using the 1H NMR spectrum of the crude material and 
this was followed by isolation of the major cis-diasteromer by flash column chromatography. In general, 
 7 
the 6-endo-trig cyclization of enones with alkyl side-chains or electron rich aromatic groups proceeded 
very cleanly giving the major cis-diastereomers in good isolated yields (54–68%) over the two steps. 
Slightly lower yields (37–51%) were observed for enones with electron deficient aromatic groups.  
 
Table 2. Scope of the 6-endo-trig cyclization. 
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a Isolated yields of cis-product over two steps. 
 
In all cases, the cis-diastereomers were formed as the major product in good diastereoselectivity. To 
rule out formation of these compounds via a reversible process, the 85:15 cis/trans-mixture of cyclized 
products formed from enone 18 were re-subjected to the cyclization reaction conditions over an 
extended period of time (5 days). However, inspection of the reaction mixture at regular intervals during 
this period using 1H NMR spectroscopy, showed no change in the ratio of diastereomers. This suggested 
that the 6-endo-trig cyclization of the enones proceeded under kinetic control. In order to obtain further 
insight into the mechanism and energetics of the cyclization step, we performed quantum-chemical 
calculations. The calculations were done at the DFT level (M06-2X/def2-TZVP+) and included a 
polarizable-continuum model of the methanol solvent. To probe substituent effects, we studied the 
reaction for formation of compounds 20 (R = Ph), 22 (R = isobutyl) and 26 (R = 4-BrPh). However, we 
found only minor differences. We therefore use only the results for formation of 20 (R = Ph) in the 
discussion below. The 6-endo-trig cyclization (Figure 2) proceeds through a transition state (TS) with a 
 9 
partially formed N–C bond (1.90 Å) and a planar, delocalized Cβ–Cα–C(O) moiety, in which the C–C 
bond lengths have equalized to 1.41 Å. Moreover, compared to the reactant, electron density has been 
shifted from the nitrogen onto the carbonyl-oxygen, increasing its negative partial charge. The 
immediate product of the cyclization is the zwitterionic ammonioenolate ZI; subsequent tautomerization 
and intramolecular neutralization afford the 2,6-cis-substituted 4-oxopipecolic acid derivative P. The 
free-energy profile of the reaction (calculated for 298 K, 1 bar) shows a relatively high activation 
energy of 108 kJ mol–1 for the cyclization. The free-energy barrier includes a sizeable entropic 
contribution of –T∆‡S = 18 kJ mol–1, due to the loss of conformational flexibility in the delocalized 
system. The formation of ZI is endergonic by 94 kJ mol–1. However, formation of the final product P is 
exergonic by –24 kJ mol–1 relative to the reactant. The initial addition step in forming ZI is therefore an 
equilibrium, shifted strongly to the reactant side. However, subsequent tautomerization/neutralization 
which is kinetically facile, is energetically highly favorable and irreversible, providing the driving force 
for product formation. This corroborates the experimental finding that the cyclized products cannot 
undergo reversible ring opening under the reaction conditions. 
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Figure 2. Free-energy profile (at 298 K, 1 bar) and optimized structures of the transition state and 
zwitterionic intermediate for the Michael addition/cyclization reaction. Energies and structures 
calculated at M06-2X/def2-TZVP+/PCM(MeOH) level. 
 
Having developed a rapid approach for the preparation of 2,6-cis-6-substituted-4-oxo-L-pipecolic acid 
analogues, we wished to show that these compounds could be reduced stereoselectively to give the 
naturally occurring (4R)-hydroxyl moiety. Initially, various borohydride reagents were screened for the 
reduction of ketone 24.12,13,21 L-Selectride showed no reduction, while sodium borohydride and sodium 
cyanoborohydride both gave the (4R)- and (4S)-alcohols in excellent diastereoselectivity (91:9) but in 
moderate yields (52% and 60%, respectively). Optimal results were achieved using sodium 
triacetoxyborohydride which gave the (4R)- and (4S)-alcohols in similar diastereoselectivity (93:7) but 
in a much higher 87% yield (Scheme 3). Using sodium triacetoxyborohydride, several other ketones 
were also reduced in excellent diastereoselectivity giving alcohols 33–37 in yields ranging from 63–
100%. 
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Scheme 3. Stereoselective reduction of 4-oxopipecolic esters. 
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To complete the synthesis of the parent 2,6-cis-6-substituted-4-hydroxypipecolic acids, several 
pipecolic esters (32–34 and 36) bearing alkyl and aryl side-chains were subjected to hydrolysis at 100 
ºC in 6 M hydrochloric acid. This gave the corresponding pipecolic acids in good to excellent yields 
(62–99%). 
 
Scheme 4. Synthesis of 4-hydroxypipecolic acids. 
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CONCLUSIONS 
In summary, a one-pot, two-step procedure involving deprotection and a Hünig’s base mediated 6-
endo-trig cyclization of α-amino acids bearing an enone side-chain has been developed leading to the 
formation of 2,6-cis-6-substituted-4-hydroxypipecolic acid derivatives in good overall yields. The 
stereochemical outcome of this cyclization can be rationalized by a Zimmerman-Traxler chair-like 
transition state where both the enone side-chain and ester moieties adopt pseudo-equatorial positions. 
The compounds formed from this process have potential for further functionalization and we have 
demonstrated one aspect of this by converting these compounds to the corresponding (4R)-hydroxyl 
derivatives by a stereoselective reduction with sodium triacetoxyborohydride. Work is currently 
underway to demonstrate the use of these compounds as general building blocks for the preparation of 
more complex systems. 
 
EXPERIMENTAL SECTION 
The synthesis of compounds 7–10, 12, 14–17 and 19 has been already described in the literature.18,19 
All reagents and starting materials were obtained from commercial sources and used as received. All 
dry solvents were purified using a solvent purification system. All reactions were performed under an 
atmosphere of argon unless otherwise mentioned. Brine refers to a saturated solution of sodium 
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chloride. Flash column chromatography was performed using silica gel 60 (35–70 µm). Aluminium-
backed plates pre-coated with silica gel 60F254 were used for thin layer chromatography and were 
visualized with a UV lamp or by staining with potassium permanganate. 1H NMR spectra were recorded 
on a NMR spectrometer at either 400 or 500 MHz and data are reported as follows: chemical shift in 
ppm relative to tetramethylsilane as the internal standard, multiplicity (s = singlet, d = doublet, t = 
triplet, q = quartet, m = multiplet or overlap of nonequivalent resonances, integration). 13C NMR spectra 
were recorded on a NMR spectrometer at either 101 or 126 MHz and data are reported as follows: 
chemical shift in ppm relative to tetramethylsilane or the solvent as internal standard (CDCl3, δ 77.0 
ppm or CD3OD, δ 44.0 ppm), multiplicity with respect to proton (deduced from DEPT experiments, C, 
CH, CH2 or CH3). Infrared spectra were recorded on a FTIR spectrometer; wavenumbers are indicated 
in cm–1. Mass spectra were recorded using electron impact, chemical ionization or fast atom 
bombardment techniques. HRMS spectra were recorded using a dual-focusing magnetic analyzer mass 
spectrometer. Melting points are uncorrected. Optical rotations were determined as solutions irradiating 
with the sodium D line (λ = 589 nm) using a polarimeter. [α]D values are given in units 10–1 deg cm2 g–
1. 
 
Methyl (2S,5E)-2-(tritylamino)-4-oxonon-5-enoate (11). Methyl (2S)-2-(tritylamino)-4-oxo-5-
(dimethoxyphosphoryl)pentanoate (8) (0.39 g, 0.78 mmol) was dissolved in acetonitrile (25 mL) at 
room temperature under argon. Anhydrous potassium carbonate (0.12 g, 0.86 mmol) and butyraldehyde 
(0.14 mL, 1.56 mmol) were added to the solution, which was then heated at 50 °C for 96 h. The reaction 
mixture was allowed to cool to room temperature and then concentrated in vacuo. The resulting residue 
was dissolved in ethyl acetate (25 mL) and washed with water (25 mL). The aqueous phase was 
extracted with ethyl acetate (25 mL) and the organic phases were combined, dried (MgSO4), filtered and 
concentrated under reduced pressure. Flash column chromatography (petroleum ether/diethyl ether 1:0 
to 2:3) afforded methyl (2S,5E)-2-(tritylamino)-4-oxonon-5-enoate (11) (0.21 g, 59%) as a yellow oil: 
IR (neat) 3316, 2955, 1736, 1667, 1443, 1204, 1173, 748 cm–1; [α]D27 = +28.6 (c 0.5, CHCl3); 1H NMR 
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(400 MHz, CDCl3) δ 0.93 (t, 3H, J = 7.3 Hz), 1.44–1.53 (m, 2H), 2.18 (qd, 2H, J = 7.0, 1.5 Hz), 2.65 
(dd, 1H, J = 15.3, 7.1 Hz), 2.79 (dd, 1H, J = 15.3, 5.2 Hz), 2.85 (d, 1H, J = 9.8 Hz), 3.27 (s, 3H), 3.66–
3.74 (m, 1H), 6.04 (dt, 1H, J = 16.0, 1.5 Hz), 6.74 (dt, 1H, J = 16.0, 7.0 Hz), 7.15–7.29 (m, 15H) ppm; 
13C NMR (101 MHz, CDCl3) δ 13.7 (CH3), 21.3 (CH2), 34.5 (CH2), 44.9 (CH2), 51.9 (CH), 53.6 (CH3), 
71.2 (C), 126.5 (3 × CH), 127.9 (6 × CH), 129.1 (6 × CH), 130.7 (CH), 145.8 (3 × C), 148.3 (CH), 
174.6 (C), 198.0 (C) ppm; MS m/z (%) 442 (MH+, 21), 364 (60), 243 (100), 198 (64), 165 (43), 97 (21), 
56 (19); HRMS (FAB) calcd. for C29H32NO3 (MH+), 442.2382, found 442.2378. 
 
Methyl (2S,5E)-2-(tritylamino)-6-(4-nitrophenyl)-4-oxohex-5-enoate (13). The reaction was carried 
out as described above using methyl (2S)-2-(tritylamino)-4-oxo-5-(dimethoxyphosphoryl)pentanoate (8) 
(0.30 g, 0.61 mmol), p-nitrobenzaldehyde (0.18 g, 1.21 mmol) and anhydrous potassium carbonate (0.09 
g, 0.67 mmol) in acetonitrile (25 mL). The mixture was heated to 50 °C for 24 h. Flash column 
chromatography (petroleum ether/diethyl ether 1:0 to 3:7) afforded methyl (2S,5E)-2-(tritylamino)-6-(4-
nitrophenyl)-4-oxohex-5-enoate (13) (0.22 g, 69%) as an off-white solid: mp 139–141 °C; IR (neat) 
2951, 1742, 1712, 1490, 1509, 1341 cm–1; [α]D25 = +43.3 (c 0.2, CHCl3); 1H NMR (400 MHz, CDCl3) δ 
2.80 (dd, 1H, J = 15.5, 6.9 Hz), 2.91 (dd, 1H, J = 15.5, 5.1 Hz), 2.95 (br s, 1H), 3.31 (s, 3H), 3.55–3.76 
(m, 1H), 6.77 (d, 1H, J = 16.2 Hz), 7.17–7.32 (m, 10H), 7.41–7.53 (m, 6H), 7.66 (d, 2H, J = 8.8 Hz), 
8.25 (d, 2H, J = 8.8 Hz) ppm; 13C NMR (101 MHz, CDCl3) δ 46.2 (CH2), 52.1 (CH3), 53.7 (CH), 71.3 
(C), 124.3 (CH), 126.6 (3 × CH), 128.0 (6 × CH), 128.8 (6 × CH), 128.9 (2 × CH), 129.6 (2 × CH), 
139.9 (CH), 140.6 (C), 145.7 (3 × C), 148.6 (C), 174.3 (C), 197.0 (C) ppm; MS m/z (%) 543 (MNa+, 
32), 443 (9), 413 (9), 351 (19), 329 (58), 243 (100), 176 (78), 154 (32); HRMS (FAB) calcd. for 
C32H28N2O5Na (MNa+), 543.1896, found 543.1903. 
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Methyl (2S,5E)-2-(tritylamino)-4-oxo-6-pyridin-3-ylhex-5-enoate (18). The reaction was carried 
out as described above using methyl (2S)-2-(tritylamino)-4-oxo-5-(dimethoxyphosphoryl)pentanoate (8) 
(0.20 g, 0.40 mmol), 3-pyridinecarboxaldehyde (0.08 mL, 0.80 mmol) and anhydrous potassium 
carbonate (0.06 g, 0.44 mmol) in acetonitrile (15 mL). The mixture was heated to 50 °C for 24 h. Flash 
column chromatography (petroleum ether/diethyl ether 8:2 to 6:4) afforded methyl (2S,5E)-2-
(tritylamino)-4-oxo-6-pyridin-3-ylhex-5-enoate (18) (0.17 g, 87%) as an orange oil: IR (NaCl) 3320, 
3056, 2949, 1737, 1691, 1662, 1612, 1490, 1447, 1415, 1203, 1025 cm–1; [〈]D = +54.3 (c 1.0, CHCl3); 
1H NMR (400 MHz, CDCl3) δ 2.78 (dd, 1H, J = 15.4, 7.0 Hz), 2.84–2.30 (m, 2H), 3.31 (s, 3H), 3.69–
3.88 (m, 1H), 6.73 (d, 1H, J = 16.1 Hz), 7.10–7.30 (m, 9H), 7.34 (dd, 1H, J = 7.9, 4.7 Hz), 7.44 (d, 1H, 
J = 16.1 Hz), 7.46–7.59 (m, 6H), 7.83 (d, 1H, J = 7.9 Hz), 8.63 (d, 1H, J = 4.7 Hz), 8.74 (s, 1H) ppm; 
13C NMR (101 MHz, CDCl3) δ 45.9 (CH2), 52.1 (CH3), 53.7 (CH), 71.3 (C), 123.9 (CH), 126.6 (3 × 
CH), 127.8 (7 × CH), 128.8 (6 × CH), 130.2 (C), 134.4 (CH), 139.4 (CH), 145.8 (3 × C), 151.2 (CH), 
151.7 (CH), 174.4 (C), 197.0 (C) ppm; MS m/z (%) 477 (MH+, 38), 399 (12), 243 (100), 233 (14), 215 
(5), 165 (21), 132 (11), 104 (4), 83 (20); HRMS (FAB) calcd. for C31H29N2O3 (MH+), 477.2178, found 
477.2180. 
 
Methyl (2S,6R)-4-oxo-6-phenylpiperidine-2-carboxylate (20). To a solution of methyl (2S,5E)-2-
(tritylamino)-4-oxo-6-phenylhex-5-enoate (9) (0.06 g, 0.13 mmol) in methanol (10 mL) at room 
temperature was added 2 M hydrochloric acid (2.5 mL). The reaction mixture was stirred for 1 h, then 
diluted with water (5 mL) and N,N-diisopropylethylamine (1.5 mL, 8.6 mmol) was added until pH 8 
was obtained. The mixture was stirred for 18 h then partitioned between ethyl acetate (20 mL) and brine 
(20 mL). The aqueous layer was separated and extracted with ethyl acetate (20 mL). The organic layers 
were combined, dried (MgSO4), filtered and concentrated under reduced pressure. Flash column 
chromatography (petroleum ether/ethyl acetate 1:0 to 3:7 with 1% triethylamine) afforded methyl 
(2S,6R)-4-oxo-6-phenylpiperidine-2-carboxylate (20) (0.02 g, 56%) as a colorless oil: IR (neat) 3325, 
2978, 2361, 1728, 1705, 1435, 1211, 756 cm–1; [α]D25 = +43.9 (c 0.9, CHCl3); 1H NMR (400 MHz, 
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CDCl3) δ 2.50–2.64 (m, 4H), 2.79 (ddd, 1H, J = 14.5, 3.5, 1.5 Hz), 3.71–3.80 (m, 4H), 3.95 (dd, 1H, J = 
10.0, 4.7 Hz), 7.30–7.43 (m, 5H) ppm; 13C NMR (101 MHz, CDCl3) δ 43.9 (CH2), 50.1 (CH2), 52.5 
(CH3), 57.9 (CH), 60.2 (CH), 126.5 (2 × CH), 128.2 (CH), 128.9 (2 × CH), 141.7 (C), 171.4 (C), 206.5 
(C) ppm; MS m/z (%) 234 (MH+, 100), 217 (2), 190 (4), 174 (12), 131 (4); HRMS (CI) calcd. for 
C13H16NO3 (MH+), 234.1130, found 234.1134. 
 
Methyl (2S,6S)-4-oxo-6-(2-methylpropyl)piperidine-2-carboxylate (22). The reaction was carried 
out as described above using methyl (2S,5E)-2-(tritylamino)-4-oxo-8-methylnon-5-enoate (10) (0.07 g, 
0.14 mmol). Flash column chromatography (petroleum ether/ethyl acetate 1:0 to 3:7 with 1% 
triethylamine) afforded methyl (2S,6S)-4-oxo-6-(2-methylpropyl)piperidine-2-carboxylate (22) (0.03 g, 
68%) as a colorless oil: IR (neat) 3332, 2957, 1740, 1716, 1437, 1216, 751 cm–1; [α]D26 = –11.2 (c 1.1, 
CHCl3); 1H NMR (400 MHz, CDCl3) δ 0.91 (d, 3H, J = 6.4 Hz), 0.93 (d, 3H, J = 6.4 Hz), 1.31–1.39 (m, 
1H), 1.46–1.53 (m, 1H), 1.69–1.80 (m, 1H), 2.03–2.16 (m, 2H), 2.38–2.45 (m, 2H), 2.69 (ddd, 1H, J = 
14.3, 3.4, 2.0 Hz), 2.88–2.95 (m, 1H), 3.65 (dd, 1H, J = 12.1, 3.4 Hz), 3.78 (s, 3H) ppm; 13C NMR (101 
MHz, CDCl3) δ 22.5 (CH3), 22.8 (CH3), 24.4 (CH), 44.6 (CH2), 46.1 (CH2), 48.8 (CH2), 52.5 (CH3), 
53.7 (CH), 58.0 (CH), 171.9 (C), 207.2 (C) ppm; MS m/z (%) 214 (MH+, 100), 187 (3), 154 (6), 130 (2), 
112 (2), 85 (8); HRMS (CI) calcd. for C11H20NO3 (MH+), 214.1443, found 214.1446. 
 
Methyl (2S,6S)-4-oxo-6-propylpiperidine-2-carboxylate (23). The reaction was carried out as 
described above using methyl (2S,5E)-2-(tritylamino)-4-oxonon-5-enoate (11) (0.10 g, 0.23 mmol). 
Flash column chromatography (petroleum ether/ethyl acetate 1:0 to 3:7 with 1% triethylamine) afforded 
methyl (2S,6S)-4-oxo-6-propylpiperidine-2-carboxylate (23) (0.03 g, 56%) as a colorless oil: IR (neat) 
3330, 2959, 2359, 1740, 1715, 1437, 1265, 1217, 750 cm–1; [α]D25 = –20.9 (c 0.5, CHCl3); 1H NMR 
(400 MHz, CDCl3) δ 0.94 (t, 3H, J = 7.0 Hz), 1.36–1.63 (m, 4H), 2.05–2.21 (m, 2H), 2.39–2.46 (m, 
2H), 2.69 (dddd, 1H, J = 14.4, 3.4, 2.1, 0.6 Hz), 2.83–2.90 (m, 1H), 3.64 (dd, 1H, J = 12.2, 3.4 Hz), 3.78 
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(s, 3H) ppm; 13C NMR (101 MHz, CDCl3) δ 14.0 (CH3), 18.8 (CH2), 38.9 (CH2), 44.5 (CH2), 48.4 
(CH2), 52.5 (CH3), 55.6 (CH), 57.9 (CH), 171.9 (C), 207.3 (C) ppm; MS m/z (%) 199 (M+, 22), 156 
(95), 140 (97), 114 (70), 98 (96), 85 (100); HRMS (EI) calcd. for C10H17NO3 (M+), 199.1208, found 
199.1212. 
 
Methyl (2S,6S)-4-oxo-6-(2-phenylethyl)piperidine-2-carboxylate (24). The reaction was carried 
out as described above using methyl (2S,5E)-2-(tritylamino)-4-oxo-8-phenyloct-5-enoate (12) (0.15 g, 
0.30 mmol). Flash column chromatography (petroleum ether/ethyl acetate 1:0 to 3:7 with 1% 
triethylamine) afforded methyl (2S,6S)-4-oxo-6-(2-phenylethyl)piperidine-2-carboxylate (24) (0.04 g, 
54%) as a white solid: mp 76–78 °C; IR (neat) 3212, 2924, 2361, 1736, 1713, 1435, 1265, 1227, 910, 
733 cm–1; [α]D26 = –15.1 (c 0.6, CHCl3); 1H NMR (400 MHz, CDCl3) δ 1.82–1.97 (m, 2H), 2.16 (ddd, 
1H, J = 14.4, 11.7, 0.9 Hz), 2.44 (ddd, 1H, J = 14.4, 12.2, 0.9 Hz), 2.48 (ddd, 1H, J = 14.4, 2.9, 2.0 Hz), 
2.70 (ddd, 1H, J = 14.4, 3.4, 2.0 Hz), 2.73–2.77 (m, 2H), 2.86–2.91 (m, 1H), 3.63 (dd, 1H, J = 12.2, 3.4 
Hz), 3.79 (s, 3H), 7.19–7.33 (m, 5H) ppm; 13C NMR (101 MHz, CDCl3) δ 30.3 (CH2), 38.3 (CH2), 44.5 
(CH2), 48.4 (CH2), 52.5 (CH3), 55.2 (CH), 57.9 (CH), 126.2 (CH), 128.5 (2 × CH), 128.6 (2 × CH), 
141.1 (C), 171.8 (C), 206.8 (C) ppm; MS m/z (%) 262 (MH+, 100), 202 (9), 156 (4), 135 (5), 113 (4), 91 
(5), 85 (11); HRMS (CI) calcd. for C15H20NO3 (MH+), 262.1443, found 262.1444. 
 
Methyl (2S,6R)-4-oxo-6-(4-nitrophenyl)piperidine-2-carboxylate (25). The reaction was carried 
out as described above using methyl (2S,5E)-2-(tritylamino)-4-oxo-6-(4-nitrophenyl)hex-5-enoate (13) 
(0.15 g, 0.29 mmol). Flash column chromatography (petroleum ether/ethyl acetate 1:0 to 3:7 with 1% 
triethylamine) afforded methyl (2S,6R)-4-oxo-6-(4-nitrophenyl)piperidine-2-carboxylate (25) (0.03 g, 
37%) as a white solid: mp 121–123 °C; IR (neat) 3347, 2955, 2361, 1721, 1605, 1520, 1350, 1219 cm–1; 
[α]D26 = +62.9 (c 1.4, CHCl3); 1H NMR (400 MHz, CDCl3) δ 2.39 (dd, 1H, J = 14.6, 11.8 Hz), 2.49–
2.58 (m, 3H), 2.76 (ddd, 1H, J = 14.6, 3.2, 1.9 Hz), 3.69–3.76 (m, 4H), 4.03 (dd, 1H, J = 11.8, 3.0 Hz), 
7.55 (d, 2H, J = 8.8 Hz), 8.17 (d, 2H, J = 8.8 Hz) ppm; 13C NMR (101 MHz, CDCl3) δ 43.7 (CH2), 49.8 
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(CH2), 52.7 (CH3), 57.7 (CH), 59.4 (CH), 124.2 (2 × CH), 127.5 (2 × CH), 147.8 (C), 148.8 (C), 171.1 
(C), 205.1 (C) ppm; MS m/z (%) 279 (MH+, 100), 249 (7), 219 (10), 203 (2), 177 (2); HRMS (CI) calcd. 
for C13H15N2O5 (MH+), 279.0981, found 279.0975. 
 
Methyl (2S,6R)-4-oxo-6-(4-bromophenyl)piperidine-2-carboxylate (26). The reaction was carried 
out as described above using methyl (2S,5E)-2-(tritylamino)-4-oxo-6-(4-bromophenyl)hex-5-enoate 
(14) (0.18 g, 0.32 mmol). Flash column chromatography (petroleum ether/ethyl acetate 1:0 to 3:7 with 
1% triethylamine) afforded methyl (2S,6R)-4-oxo-6-(4-bromophenyl)piperidine-2-carboxylate (26) 
(0.04 g, 39%) as a white solid: mp 166–168 °C (decomposition): IR (neat) 3327, 2954, 1721, 1435, 
1250, 1227, 787 cm–1; [α]D27 = +29.9 (c 1.1, CHCl3); 1H NMR (400 MHz, CDCl3) δ 2.46 (ddd, 1H, J = 
14.5, 11.6, 0.8 Hz), 2.51–2.56 (m, 2H), 2.59 (ddd, 1H, J = 14.5, 11.6, 0.8 Hz), 2.79 (ddd, 1H, J = 14.5, 
3.0, 2.0 Hz), 3.75 (dd, 1H, J = 11.6, 3.0 Hz), 3.79 (s, 3H), 3.92 (dd, 1H, J = 11.6, 3.0 Hz), 7.30 (d, 2H, J 
= 8.4 Hz), 7.50 (d, 2H, J 8.4 Hz) ppm; 1H NMR (126 MHz, CDCl3) δ 43.8 (CH2), 50.0 (CH2), 52.6 
(CH3), 57.8 (CH), 59.6 (CH), 122.0 (C), 128.3 (2 × CH), 132.0 (2 × CH), 140.8 (C), 171.3 (C), 206.0 
(C) ppm; MS m/z (%) 314 (MH+, 100), 252 (3), 234 (8), 167 (2), 113 (5); HRMS (CI) calcd. for 
C13H1581BrNO3 (MH+), 314.0216, found 314.0219. 
 
Methyl (2S,6R)-4-oxo-6-(4-methoxyphenyl)piperidine-2-carboxylate (27). The reaction was 
carried out as described above using methyl (2S,5E)-2-(tritylamino)-4-oxo-6-(4-methoxyphenyl)hex-5-
enoate (15) (0.05 g, 0.10 mmol). Flash column chromatography (petroleum ether/ethyl acetate 1:0 to 3:7 
with 1% triethylamine) afforded methyl (2S,6R)-4-oxo-6-(4-methoxyphenyl)piperidine-2-carboxylate 
(27) (0.02 g, 56%) as a colorless oil: IR (neat) 3317, 2955, 2361, 1743, 1713, 1512, 1250, 1219, 756 
cm–1; [α]D25 = +38.4 (c 1.1, CHCl3); 1H NMR (400 MHz, CDCl3) δ 2.52–2.55 (m, 3H), 2.59 (dd, 1H, J 
= 14.4, 12.2 Hz), 2.78 (dd, 1H, J = 14.4, 3.3 Hz), 3.75 (dd, 1H, J = 12.2, 3.3 Hz), 3.78 (s, 3H), 3.81 (s, 
3H), 3.90 (dd, 1H, J = 8.2, 6.7 Hz), 6.90 (d, 2H, J = 8.8 Hz), 7.33 (d, 2H, J = 8.8 Hz) ppm; 13C NMR 
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(101 MHz, CDCl3) δ 43.9 (CH2), 50.2 (CH2), 52.5 (CH3), 55.3 (CH3), 57.9 (CH), 59.7 (CH), 114.2 (2 × 
CH), 127.7 (2 × CH), 133.9 (C), 159.4 (C), 171.4 (C), 206.6 (C) ppm; MS m/z (%) 263 (M+, 53), 204 
(25), 161 (100), 134 (28), 84 (32), 49 (33); HRMS (EI) calcd. for C14H17NO4 (M+), 263.1158, found 
263.1161. 
 
Methyl (2S,6R)-4-oxo-6-(3-ethenylphenyl)piperidine-2-carboxylate (28). The reaction was carried 
out as described above using methyl (2S,5E)-2-(tritylamino)-4-oxo-6-(3-ethenylphenyl)hex-5-enoate 
(16) (0.15 g, 0.30 mmol). Flash column chromatography (petroleum ether/ethyl acetate 1:0 to 3:7 with 
1% triethylamine) afforded methyl (2S,6R)-4-oxo-6-(3-ethenylphenyl)piperidine-2-carboxylate (28) 
(0.035 g, 45%) as a colorless oil: IR (neat) 3321, 2953, 2359, 1740, 1717, 1437, 1219, 802 cm–1; [〈]D26 
= +58.7 (c 1.0, CHCl3); 1H NMR (400 MHz, CDCl3) δ 2.50–2.57 (m, 2H), 2.61 (dd, 1H, J = 14.6, 12.2 
Hz), 2.79 (ddd, 1H, J = 14.6, 3.5, 1.5 Hz), 3.77 (dd, 1H, J = 12.2, 3.5 Hz), 3.79 (s, 3H), 3.95 (dd, 1H, J 
= 10.2, 4.7 Hz), 5.28 (d, 1H, J = 11.0 Hz), 5.78 (d, 1H, J = 17.6 Hz), 6.72 (dd, 1H, J = 17.6, 11.0 Hz), 
7.25–7.39 (m, 3H), 7.46 (s, 1H) ppm; 13C NMR (101 MHz, CDCl3) δ 43.8 (CH2), 50.1 (CH2), 52.6 
(CH3), 57.9 (CH), 60.2 (CH), 114.6 (CH2), 124.4 (CH), 125.9 (CH), 126.0 (CH), 129.1 (CH), 136.5 
(CH), 138.2 (C), 142.0 (C), 171.4 (C), 206.5 (C) ppm; MS m/z (%) 260 (MH+, 100), 225 (16), 172 (12), 
113 (12), 81 (26), 69 (42); HRMS (CI) calcd. for C15H18NO3 (MH+), 260.1287, found 260.1281. 
 
Methyl (2S,6R)-4-oxo-6-(naphthalen-2-yl)piperidine-2-carboxylate (29). The reaction was carried 
out as described above using methyl (2S,5E)-2-(tritylamino)-4-oxo-6-(naphthalen-2-yl)hex-5-enoate 
(17) (0.15 g, 0.29 mmol). Flash column chromatography (petroleum ether/ethyl acetate 1:0 to 3:7 with 
1% triethylamine) afforded methyl (2S,6R)-4-oxo-6-(naphthalen-2-yl)piperidine-2-carboxylate (29) 
(0.055 g, 66%) as a white solid: mp 115–117 °C; IR (neat) 3325, 2953, 2360, 1736, 1712, 1435, 1248, 
1211, 820, 750 cm–1; [α]D25 = +36.9 (c 1.2, CHCl3); 1H NMR (400 MHz, CDCl3) δ 2.64–2.72 (m, 4H), 
2.86 (ddd, 1H, J = 14.5, 3.5, 1.3 Hz), 3.82 (s, 3H), 3.85 (dd, 1H, J = 12.1, 3.5 Hz), 4.15 (dd, 1H, J = 9.3, 
5.4 Hz), 7.47–7.57 (m, 3H), 7.84–7.90 (m, 4H) ppm; 13C NMR (126 MHz, CDCl3) δ 43.9 (CH2), 50.1 
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(CH2), 52.6 (CH3), 58.0 (CH), 60.3 (CH), 124.5 (CH), 125.3 (CH), 126.2 (CH), 126.4 (CH), 127.7 
(CH), 127.9 (CH), 128.7 (CH), 133.2 (C), 133.4 (C), 139.1 (C), 171.4 (C), 206.4 (C) ppm; MS m/z (%) 
284 (MH+, 100), 243 (7), 224 (2), 182 (2), 156 (2); HRMS (CI) calcd. for C17H18NO3 (MH+), 284.1287, 
found 284.1287. 
 
Methyl (2S,6R)-4-oxo-6-(pyridine-3-yl)piperidine-2-carboxylate (30). The reaction was carried out 
as described above using methyl (2S,5E)-2-(tritylamino)-4-oxo-6-(pyridin-3-yl)hex-5-enoate (18) (0.14 
g, 0.30 mmol). Flash column chromatography (petroleum ether/ethyl acetate 1:0 to 3:7 with 1% 
triethylamine) afforded methyl (2S,6R)-4-oxo-6-(pyridine-3-yl)piperidine-2-carboxylate (30) (0.03 g, 
43%) as an off-white solid: mp 123–125 °C; IR (neat) 3264, 2924, 1713, 1435, 1227, 718 cm–1; [〈]D26 = 
+34.8 (c 1.0, CHCl3); 1H NMR (500 MHz, CDCl3) δ 2.50 (dd, 1H, J = 14.3, 11.2 Hz) 2.53–2.58 (m, 
1H), 2.60 (dd, 1H, J = 13.6, 12.2 Hz), 2.79 (ddd, 1H, J = 14.3, 3.5, 1.8 Hz), 3.74–3.78 (m, 4H), 4.00 
(dd, 1H, J = 11.2, 3.5 Hz), 7.31 (dd, 1H, J = 7.8, 4.2 Hz), 7.78 (d, 1H, J = 7.8 Hz), 8.56 (d, 1H, J = 4.2 
Hz), 8.63 (s, 1H) ppm; 13C NMR (126 MHz, CDCl3) δ 43.8 (CH2), 49.6 (CH2), 52.6 (CH3), 57.7 (CH), 
57.8 (CH), 123.8 (CH), 134.2 (CH), 137.2 (C), 148.4 (CH), 149.7 (CH), 171.1 (C), 205.5 (C) ppm; MS 
m/z (%) 234 (M+, 8), 175 (69), 133 (22), 86 (95), 84 (95), 49 (100); HRMS (EI) calcd. for C12H14N2O3 
(M+), 234.1004, found 234.1005. 
 
Methyl (2S,6R)-4-oxo-6-(3'-nitrobiphen-4-yl)piperidine-2-carboxylate (31). The reaction was 
carried out as described above using methyl (2S,5E)-2-(tritylamino)-4-oxo-6-(3’-nitrobiphen-4-yl)hex-
5-enoate (19) (0.11 g, 0.18 mmol). Flash column chromatography (petroleum ether/ethyl acetate 1:0 to 
3:7 with 1% triethylamine) afforded methyl (2S,6R)-4-oxo-6-(3'-nitrobiphen-4-yl)piperidine-2-
carboxylate (31) (0.033 g, 51%) as a yellow oil: IR (neat) 3325, 2924, 1721, 1528, 1350, 1219, 733 cm–
1; [〈]D26 = +41.2  (c 1.0, CHCl3); 1H NMR (500 MHz, CDCl3) δ 2.55 (dd, 1H, J = 14.2, 11.2 Hz), 2.61 
(ddd, 1H, J = 14.2, 3.6, 1.9 Hz), 2.62 (dd, 1H, J = 14.5, 12.2 Hz), 2.82 (ddd, 1H, J = 14.5, 3.3, 1.8 Hz), 
3.77–3.82 (m, 4H), 4.03 (dd, 1H, J = 11.2, 3.6 Hz), 7.53–7.56 (m, 2H), 7.59–7.65 (m, 3H), 7.91 (ddd, 
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1H, J = 8.0, 1.6, 1.0 Hz), 8.20 (ddd, 1H, J = 8.0, 2.0, 1.0 Hz), 8.44 (t, 1H, J = 2.0 Hz) ppm; 13C NMR 
(101 MHz, CDCl3) δ 43.9 (CH2), 50.0 (CH2), 52.5 (CH3), 58.9 (CH), 59.8 (CH), 121.9 (CH), 122.2 
(CH), 127.4 (2 × CH), 127.6 (2 × CH), 129.8 (CH), 132.9 (CH), 138.5 (C), 142.2 (C), 142.2 (C), 148.8 
(C), 171.3 (C), 206.1 (C) ppm; MS m/z (%) 354 (M+, 30), 295 (91), 252 (100), 84 (32), 49 (30); HRMS 
(EI) calcd. for C19H18N2O5 (M+), 354.1216, found 354.1210. 
 
Methyl (2S,4R,6S)-4-hydroxy-6-(2-phenylethyl)piperidine-2-carboxylate (32). To a solution of 
methyl (2S,6S)-4-oxo-6-(2-phenylethyl)piperidine-2-carboxylate (24) (0.05 g, 0.19 mmol) in 
tetrahydrofuran (10 mL) at room temperature was added sodium triacetoxyborohydride (0.05 g, 0.23 
mmol) and the reaction stirred for 48 h. The mixture was quenched with 2 M hydrochloric acid (5 mL) 
then partitioned between a saturated solution of sodium hydrogen carbonate (15 mL) and ethyl acetate 
(15 mL). The organic phase was separated, washed with brine, dried (MgSO4), filtered and concentrated 
under reduced pressure. Flash column chromatography (petroleum ether/ethyl acetate 1:0 to 3:7 with 
1% triethylamine) afforded the desired product 32 (0.04 g, 87%) as a colorless oil: IR (neat) 3330, 2946, 
2360, 1739, 1436, 1262, 1213, 700 cm–1; [α]D29 = –2.2 (c 0.7, CHCl3); 1H NMR (400 MHz, CDCl3) δ 
0.99 (q, 1H, J = 11.2 Hz), 1.26 (q, 1H, J = 11.8 Hz), 1.65–1.81 (m, 2H), 1.94–1.99 (m, 1H), 2.22–2.28 
(m, 1H), 2.49–2.56 (m, 1H), 2.58–2.70 (m, 2H), 3.30 (dd, 1H, J = 11.8, 2.7 Hz), 3.60–3.69 (m, 4H), 
7.10–7.23 (m, 5H) ppm; 13C NMR (126 MHz, CDCl3) δ 32.2 (CH2), 38.2 (CH2), 38.5 (CH2), 41.5 
(CH2), 52.2 (CH3), 53.6 (CH), 57.2 (CH), 68.9 (CH), 125.9 (CH), 128.3 (2 × CH), 128.5 (2 × CH), 
141.7 (C), 172.9 (C) ppm; MS m/z (%) 263 (M+, 8), 204 (100), 187 (12), 158 (49), 140 (28), 91 (57), 82 
(16); HRMS (EI) calcd. for C15H21NO3 (M+), 263.1521, found 263.1519. 
  
Methyl (2S,4R,6S)-4-hydroxy-6-(2-methylpropyl)piperidine-2-carboxylate (33). The reaction was 
carried out as described above using methyl (2S,6S)-6-(2-methylpropyl)-4-oxopiperidine-2-carboxylate 
(22) (0.033 g, 0.13 mmol). Flash column chromatography (DCM/methanol 19:1 with 1% triethylamine) 
afforded the desired product 33 (0.021 g, 63%) as a colorless oil: IR (neat) 3329, 2955, 2360, 1735, 
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1437, 1264, 1213, 1160 cm–1; [α]D26 = –11.4 (c 1.0, CHCl3); 1H NMR (500 MHz, CDCl3) δ 0.89 (d, 3H, 
J = 6.4 Hz), 0.91 (d, 3H, J = 6.4 Hz), 0.99 (dt, 1H, J = 11.8, 11.2 Hz), 1.24–1.30 (m, 1H), 1.31 (td, 1H, J 
= 11.8, 11.3 Hz), 1.36–1.44 (m, 1H), 1.65–1.80 (m, 3H), 1.97 (dquint, 1H, J = 12.1, 2.2 Hz),  2.31 
(dquint, 1H, J = 11.8, 2.2 Hz), 2.59–2.66 (m, 1H), 3.38 (dd, 1H, J = 11.8, 2.7 Hz), 3.70 (tt, 1H, J = 11.3, 
4.5 Hz), 3.73 (s, 3H) ppm; 13C NMR (126 MHz, CDCl3) δ 22.5 (CH3), 22.9 (CH3), 24.4 (CH), 38.6 
(CH2), 42.1 (CH2), 45.9 (CH2), 52.0 (CH2), 52.1 (CH), 57.3 (CH), 69.0 (CH), 172.8 (C) ppm; MS m/z 
(%) 216 (MH+, 48), 198 (34), 158 (65), 156 (100), 140 (32), 112 (37), 80 (18); HRMS (CI) calcd. for 
C11H22NO3 (MH+), 216.1600, found 216.1597. 
 
Methyl (2S,4R,6R)-4-hydroxy-6-(4-methoxyphenyl)piperidine-2-carboxylate (34). The reaction 
was carried out as described above using methyl (2S,6R)-6-(4-methoxyphenyl)-4-oxopiperidine-2-
carboxylate (27) (0.03 g, 0.13 mmol). Flash column chromatography (petroleum ether/ethyl acetate 1:0 
to 3:7 with 1% triethylamine) afforded the desired product 34 (0.03 g, 96%) as a colorless oil: IR (neat) 
3333, 2926, 2363, 1738, 1612, 1514, 1245, 1034, 831 cm–1; [α]D25 = +16.4 (c 0.9, CHCl3); 1H NMR 
(500 MHz, CDCl3) δ 1.47 (dd, 1H, J = 11.5, 5.0 Hz), 1.52 (dd, 1H, J = 11.8, 5.5 Hz), 2.08–2.12 (m, 
1H), 2.38–2.42 (m, 1H), 3.52 (dd, 1H, J = 11.8, 2.6 Hz), 3.64 (dd, 1H, J = 11.5, 2.5 Hz), 3.74 (s, 3H), 
3.80 (s, 3H), 3.79–3.88 (m, 1H), 6.85–6.88 (m, 2H), 7.29–7.32 (m, 2H) ppm; 13C NMR (101 MHz, 
CDCl3) δ 37.6 (CH2), 43.1 (CH2), 52.2 (CH3), 55.3 (CH3), 57.5 (CH), 58.5 (CH), 69.3 (CH), 113.9 (2 × 
CH), 128.0 (2 × CH), 135.2 (C), 159.0 (C), 172.5 (C) ppm; MS m/z (%) 266 (MH+, 100), 248 (30), 234 
(6), 206 (4), 178 (3), 158 (3), 130 (2); HRMS (CI) calcd. for C14H20NO4 (MH+), 266.1392, found 
266.1396. 
 
Methyl (2S,4R,6R)-4-hydroxy-6-(3-ethenylphenyl)piperidine-2-carboxylate (35). The reaction 
was carried out as described above using methyl (2S,6R)-4-oxo-6-(3-ethenylphenyl)piperidine-2-
carboxylate (28) (0.015 g, 0.06 mmol). Flash column chromatography (petroleum ether/ethyl acetate 1:0 
to 3:7 with 1% triethylamine) afforded the desired product 35 (0.01 g, 76%) as a colorless oil: IR (neat) 
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3320, 2924, 2360, 1735, 1437, 1216, 1013, 910, 802 cm–1; [〈]D26 = +27.3 (c 0.6, CHCl3); 1H NMR (400 
MHz, CDCl3) δ 1.52 (q, 2H, J = 11.8 Hz), 1.60–2.00 (br s, 1H), 2.14 (dquint, 1H, J = 11.8, 2.3 Hz), 2.43 
(dquint, 1H, J = 11.8, 2.3 Hz), 3.54 (dd, 1H, J = 11.8, 2.2 Hz), 3.70 (dd, 1H, J = 11.8, 2.3 Hz), 3.75 (s, 
3H), 3.87 (tt, 1H, J = 11.8, 2.3 Hz), 5.25 (dd, 1H, J 10.9, 0.4 Hz), 5.76 (dd, 1H, J = 17.6, 0.4 Hz), 6.71 
(dd, 1H, J = 17.6, 10.9 Hz), 7.26–7.32 (m, 2H), 7.34 (dt, 1H, J = 7.1, 1.7 Hz), 7.43 (s, 1H) ppm; 13C 
NMR (126 MHz, CDCl3) δ 37.6 (CH2), 43.1 (CH2), 52.2 (CH3), 57.5 (CH), 59.1 (CH), 69.4 (CH), 114.1 
(CH2), 124.7 (CH), 125.4 (CH), 126.3 (CH), 128.7 (CH), 136.7 (CH), 137.9 (C), 143.3 (C), 172.4 (C) 
ppm; MS m/z (%) 261 (M+, 42), 202 (100), 159 (21), 130 (12), 83 (78); HRMS (EI) calcd. for 
C15H19NO3 (M+), 261.1365, found 261.1364. 
 
Methyl (2S,4R,6R)-4-hydroxy-6-(naphthalen-2-yl)piperidine-2-carboxylate (36). The reaction was 
carried out as described above using methyl (2S,6R)-4-oxo-6-(naphthalen-2-yl)piperidine-2-carboxylate 
(29) (0.07 g, 0.24 mmol). Flash column chromatography (petroleum ether/ethyl acetate 1:0 to 3:7 with 
1% triethylamine) afforded the desired product 36 (0.07 g, 100%) as a white solid: mp 109–111 °C; IR 
(neat) 3275, 2361, 1728, 1431, 1223, 1123, 1049, 826 cm–1; [α]D25 = +25.3 (c 0.1, CHCl3); 1H NMR 
(400 MHz, CDCl3) δ 1.53 (dd, 1H, J = 11.5, 8.4 Hz), 1.58 (dd, 1H, J = 11.9, 8.4 Hz), 2.17–2.22 (m, 
1H), 2.41–2.47 (m, 1H), 3.57 (dd, 1H, J = 11.9, 2.6 Hz), 3.75 (s, 3H), 3.84 (dd, 1H, J = 11.5, 2.3 Hz), 
3.87–3.93 (m, 1H), 7.43–7.51 (m, 3H), 7.80–7.84 (m, 4H) ppm; 13C NMR (126 MHz, CDCl3) δ 37.6 
(CH2), 43.2 (CH2), 52.3 (CH3), 57.5 (CH), 59.2 (CH), 69.3 (CH), 125.1 (CH), 125.2 (CH), 125.8 (CH), 
126.1 (CH), 127.6 (CH), 127.9 (CH), 128.3 (CH), 133.0 (C), 133.4 (C), 140.5 (C), 172.6 (C) ppm; MS 
m/z (%) 286 (MH+, 100), 266 (17), 226 (4), 209 (2), 155 (2), 95 (3); HRMS (CI) calcd. for C17H20NO3 
(MH+), 286.1443, found 286.1444. 
 
Methyl (2S,4R,6R)-4-hydroxy-6-(3'-nitrobiphen-4-yl)piperidine-2-carboxylate (37). The reaction 
was carried out as described above using methyl (2S,6R)-4-oxo-6-(3'-nitrobiphen-4-yl)piperidine-2-
carboxylate (31) (0.008 g, 0.02 mmol). Flash column chromatography (petroleum ether/ethyl acetate 1:0 
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to 3:7 with 1% triethylamine) afforded the desired product 37 (0.008 g, 100%) as a yellow oil: IR (neat) 
3344, 2924, 2359, 1734, 1532, 1349, 1213, 668 cm–1; [〈]D26 = +15.2 (c 3.4, CHCl3); 1H NMR (400 MHz, 
CDCl3) δ 1.53 (q, 1H, J = 11.8 Hz), 1.54 (q, 1H, J = 11.8 Hz), 1.61 (br s, 1H), 2.18 (dquint, 1H, J = 
11.8, 2.3 Hz), 2.46 (dquint, 1H, J = 11.8, 2.3 Hz), 3.57 (dd, 1H, J = 11.8, 2.6 Hz), 3.77 (s, 3H), 3.75–
3.81 (m, 1H), 3.86–3.95 (m, 1H), 7.50–7.55 (m, 2H), 7.58–7.64 (m, 3H), 7.91 (ddd, 1H, J = 7.7, 1.6, 1.0 
Hz), 8.20 (ddd, 1H, J = 8.2, 2.2, 1.0 Hz), 8.45 (t, 1H, J = 1.9 Hz) ppm; 13C NMR (101 MHz, CDCl3) δ 
37.6 (CH2), 43.2 (CH2), 52.3 (CH3), 57.4 (CH), 58.7 (CH), 69.3 (CH), 121.9 (CH), 122.0 (CH), 127.3 (2 
× CH), 127.6 (2 × CH), 129.7 (CH), 132.9 (CH), 138.0 (C), 142.5 (C), 143.6 (C), 148.7 (C), 172.4 (C) 
ppm; MS m/z (%) 357 (MH+, 6), 307 (48), 282 (3), 189 (5), 164 (14), 138 (100), 81 (5); HRMS (CI) 
calcd. for C19H21N2O5 (MH+), 357.1450, found 357.1456.                                              
 
(2S,4R,6S)-4-Hydroxy-6-(2-phenylethyl)piperidine-2-carboxylic acid (38). Methyl (2S,4R,6S)-4-
hydroxy-6-(2-phenylethyl)piperidine-2-carboxylate (32) (0.06 g, 0.22 mmol) was dissolved in 6 M 
hydrochloric acid (5 mL) and heated to 100 °C for 48 h. The reaction mixture was cooled and 
concentrated under reduced pressure to afford a white solid. This was washed with acetone then dried 
under reduced pressure to afford the desired product 38 (0.04 g, 62%) as a white solid: mp 219–221 °C 
(decomposition); IR (neat) 3408, 2921, 1757, 1453, 1184, 1066, 751, 699 cm–1; [α]D26 = +50.3 (c 0.1, 
MeOH); 1H NMR (500 MHz, CD3OD) δ 1.38 (q, 1H, J = 12.8 Hz), 1.59 (q, 1H, J = 12.8 Hz), 1.90–1.98 
(m, 1H), 2.10–2.16 (m, 1H), 2.33–2.36 (m, 1H), 2.52–2.55 (m, 1H), 2.67–2.73 (m, 1H), 2.78–2.84 (m, 
1H), 3.23–3.27 (m, 1H), 3.88–3.94 (m, 1H), 4.06 (dd, 1H, J = 11.5, 2.1 Hz), 7.18–7.31 (m, 5H) ppm; 
13C NMR (101 MHz, CD3OD) δ 32.3 (CH2), 35.8 (2 × CH2), 37.6 (CH2), 56.0 (CH), 57.1 (CH), 66.3 
(CH), 127.5 (CH), 129.4 (2 × CH), 129.8 (2 × CH), 141.6 (C), 170.6 (C) ppm; MS m/z (%) 249 (M+, 9), 
226 (7), 204 (100), 160 (25), 144 (92), 126 (33), 117 (22), 91 (81); HRMS (EI) calcd. for C14H19NO3, 
249.1365, found 249.1368. 
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(2S,4R,6S)-4-Hydroxy-6-(2-methylpropyl)piperidine-2-carboxylic acid (39). The reaction was 
carried out as described above using methyl (2S,4R,6S)-4-hydroxy-6-(2-methylpropyl)piperidine-2-
carboxylate (33) (0.029 g, 0.084 mmol). This gave the desired product 39 (0.027 g, 99%) as a white 
solid: mp 247–249 °C; IR (neat) 3362, 2926, 2074, 1732, 1117, 972 cm–1; [α]D25 = –2.4 (c 2.5, MeOH); 
1H NMR (500 MHz, CD3OD) δ 0.96 (d, 3H, J = 6.1 Hz), 1.00 (d, 3H, J = 6.1 Hz), 1.27–1.40 (br m, 1H), 
1.54–1.66 (br m, 3H), 1.72–1.83 (br m, 1H), 2.24 (br d, 1H, J = 13.4 Hz), 2.53 (br d, 1H, J = 12.5 Hz), 
3.24–3.34 (br m, 1H), 3.90–3.98 (br m, 1H), 4.04 (br d, 1H, J = 12.5 Hz) ppm; 13C NMR (126 MHz, 
CD3OD) δ 21.9 (CH3), 23.7 (CH3), 25.4 (CH), 35.9 (CH2), 38.1 (CH2), 43.0 (CH2), 55.1 (CH), 57.4 
(CH), 66.4 (CH), 170.6 (C) ppm; MS m/z (%) 202 (MH+, 100), 184 (25), 100 (41); HRMS (CI) calcd. 
for C10H20NO3, 202.1443, found 202.1445. 
 
(2S,4R,6R)-4-Hydroxy-6-(4-methoxyphenyl)piperidine-2-carboxylic acid (40). The reaction was 
carried out as described above using methyl (2S,4R,6R)-4-hydroxy-6-(4-methoxyphenyl)piperidine-2-
carboxylate (34) (0.03 g, 0.11 mmol). This gave the desired product 40 (0.02 g, 67%) as a white solid: 
mp 173–175 °C (decomposition); IR (neat) 3323, 2926, 1732, 1612, 1518, 1254, 1182, 1022, 831 cm–1; 
[α]D29 = –21.0 (c 1.0, MeOH); 1H NMR (400 MHz, CD3OD) δ 1.74 (q, 1H, J = 12.8 Hz), 1.94 (q, 1H, J 
= 12.8 Hz), 2.24–2.27 (m, 1H), 2.60–2.63 (m, 1H), 3.82 (s, 3H), 4.07–4.11 (m, 1H), 4.22–4.24 (m, 1H), 
4.34–4.36 (m, 1H), 7.02 (d, 2H, J = 8.4 Hz), 7.45 (d, 2H, J = 8.8 Hz) ppm; 13C NMR (101 MHz, 
CD3OD) δ 35.4 (CH2), 39.3 (CH2), 55.9 (CH3), 57.8 (CH), 59.5 (CH), 66.9 (CH), 115.6 (2 × CH), 128.6 
(C), 130.2 (2 × CH), 162.2 (C), 170.4 (C) ppm; MS m/z (%) 251 (M+, 42), 234 (19), 206 (100), 179 
(28), 163 (74), 135 (62), 91 (18); HRMS (EI) calcd. for C13H17NO4 (M+), 251.1158, found 251.1156. 
 
(2S,4R,6R)-4-Hydroxy-6-(naphthalen-2-yl)piperidine-2-carboxylic acid (41). The reaction was 
carried out as described above using methyl (2S,4R,6R)-4-hydroxy-6-(naphthalen-2-yl)piperidine-2-
carboxylate (36) (0.06 g, 0.21 mmol). This gave the desired product 41 (0.05 g, 70%) as a white solid: 
mp 203–205 °C (decomposition); IR (neat) 3327, 2951, 1744, 1622, 1410, 1213, 1055, 814 cm–1; [α]D27 
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= +10.1 (c 1.1, MeOH); 1H NMR (400 MHz, CD3OD) δ 1.86 (q, 1H, J = 13.0 Hz), 2.08 (q, 1H, J = 12.8 
Hz), 2.39–2.41 (m, 1H), 2.67–2.70 (m, 1H), 4.17–4.23 (m, 1H), 4.37 (dd, 1H, J = 13.0, 2.6 Hz), 4.64 
(dd, 1H, J = 12.8, 1.9 Hz), 7.54–7.58 (m, 2H), 7.66 (dd, 1H, J = 8.5, 1.4 Hz), 7.91 (dd, 1H J = 6.1, 3.4 
Hz), 7.95 (dd, 1H, J = 6.1, 3.4 Hz), 7.99 (d, 1H, J = 8.5 Hz), 8.07 (br s, 1H) ppm; 1H NMR (101 MHz, 
CD3OD) δ 35.5 (CH2), 39.6 (CH2), 58.0 (CH), 60.1 (CH), 66.9 (CH), 125.6 (CH), 128.0 (CH), 128.3 
(CH), 128.3 (CH), 128.9 (CH), 129.3 (CH), 130.3 (CH), 134.2 (C), 134.7 (C), 135.1 (C), 170.4 (C) 
ppm; MS m/z (%) 271 (M+, 25), 226 (100), 205 (36), 183 (40), 155 (48), 128 (21), 91 (14); HRMS (EI) 
calcd. for C16H17NO3 (M+), 271.1209, found 271.1205. 
 
Computational details. All calculations were done with the program Gaussian 0922 using the M06-
2X exchange-correlation functional,23 which has been shown23,24 to provide accurate results for main-
group thermochemistry and activation barriers. The def2-TZVP basis set,25 which affords results close 
to the basis-set limit for density-functional theory, was augmented for all atoms by one diffuse basis 
function per valence orbital. The exponents of the additional functions were derived from the existing 
ones according to a simple geometric progression (even-tempered). We refer to the augmented set as 
def2-TZVP+. All calculations included the effects of the methanol solvent at the level of the IEF-PCM 
polarizable continuum model as implemented in Gaussian 09. Default parameters for SCF and geometry 
convergence were used. The nature of stationary points was verified by the appropriate number of 
imaginary frequencies, obtained from analytical second derivatives. Thermochemical data were 
calculated within the standard rigid-rotor/harmonic-oscillator framework at 298 K, 100 kPa. 
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SUPPORTING INFORMATION AVAILABLE. NOE data for compounds 32–37 and, 1H and 13C 
NMR spectra for all new compounds. This material is available free of charge via the Internet at 
http://pubs.acs.org. 
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